Emerging role of nanocarriers based topical delivery of anti-fungal agents in combating growing fungal infections.
fungal infection
nanocarriers
new targets
topical delivery
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
20
05
2020
revised:
14
06
2020
accepted:
19
06
2020
pubmed:
27
6
2020
medline:
15
5
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
The incidences of fungal infections have greatly increased over the past few years, particularly in humid and industrialized areas. The severity of such infections ranges from being asymptomatic-mild to potentially life-threatening systemic infections. There are limited classes of drugs that are approved for the treatment of such infections like polyenes, azoles, and echinocandins. Some fungi have developed resistance to these drugs. Therefore, to counter drug resistance, intensive large scale studies on novel targeting strategies and formulations are being conducted, which have gained impetus lately. Conventional formulations have limitations such as higher doses, frequent dosing, and several side effects. Such limiting factors have paved the path for the emergence of nanotechnology and its applications. This further gave formulation scientists the possibility of encapsulating the existing potential drug moieties into nanocarriers, which when loaded into gels or creams provided prolonged release and improved permeation, thus giving on-target effect. This review thus discusses the newer targeting strategies and the role of nanocarriers that could be administered topically for the treatment of various fungal infections. Furthermore, this approach opens newer avenues for continued and sustained research in pharmaceuticals with much more effective outcomes.
Substances chimiques
Antifungal Agents
0
Azoles
0
Echinocandins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13905Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Bongomin F, Gago S, Oladele R, Denning D. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi. 2017;3(4):57.
Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527-1534.
Brown GD, Brown GD, Denning DW, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):13.
Arnold TM, Dotson E, Sarosi GA, Hage CA. Traditional and emerging antifungal therapies. Proc Am Thorac Soc. 2010;7(19):222-228.
Gupta M, Sharma V, Chauhan NS. Promising novel nanopharmaceuticals for improving topical antifungal drug delivery. In: Grumezescu AM, ed. Nano- and Microscale Drug Delivery Systems. Amsterdam, Netherlands: Elsevier Inc; 2017:197-228.
States U, Benedict K, Iii GRT, Deresinski S, Chiller T. Mycotic infections acquired outside areas of known. Emerg Infect Dis. 2015;21(11):1935-1941.
Zijlstra EE, van de WWJ S, Welsh O, Mahgoub ES, Goodfellow M, Fahal AH. Mycetoma: a unique neglected tropical disease. Lancet Infect Dis. 2016;16(1):100-112.
Paes RDA, Schubach AO. Sporothrix schenckii and sporotrichosis. Clin Microbiol Rev. 2011;24(4):633-654.
Ghannoum MA, Edwards KE, Edwards JE. Pathogenesis of fungal infections. Bailliere's. Clin Infect Dis. 1995;2(1):1-16.
Williams D, Lewis M, Williams D, Lewis M. Pathogenesis and treatment of oral candidosis. J Oral Microbiol. 2011;3:5771.
Parente-Rocha JA, Bailão AM, Amaral AC, et al. Antifungal resistance, metabolic routes as drug targets, and new antifungal agents: an overview about endemic dimorphic fungi. Mediators Inflamm. 2017;2017:1-16.
Ryder NS, Frank I, Dupont M. Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate toglnitter. Antimicrob Agents Chemother. 1986;29(5):858-860.
Polak A, Roche H. Mode of action of morpholine derivatives. Ann N Y Acad Sci. 1988;544(1):221-228.
Scorzoni L, de Paula ACA, Marcos CM, et al. Antifungal therapy: new advances in the understanding and treatment of mycosis. Front Microbiol. 2017;8:1-23.
Whitesell L, Robbins N, Huang DS, et al. Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus. Nat Commun. 2019;10:1-17.
Juvvadi PR, Chan S, Heitman J, Steinbach WJ. Calcineurin in fungal virulence and drug resistance: prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. Virulence. 2017;8(2):186-197.
Singhvi G, Dubey SK, Patil S, Girdhar V. Nanocarriers for topical drug delivery: approaches and advancements. Nanosci Nanotechnol. Asia. 2019;08(3):329-336.
Satish M, Shridhar S, Kiran B. Optimization and characterization of sertaconazole nitrate flexisomes embedded in hydrogel for improved antifungal activity. J Liposome Res. 2019;29(1):10-20.
Butani D, Yewale C, Misra A. Topical amphotericin B solid lipid nanoparticles: design and development. Colloids Surfaces B Biointerfaces. 2016;139:17-24.
Kareem F, Bhayo AM, Imran M, Shah MR, Khan KM, Malik MI. Enhanced therapeutic efficacy of clotrimazole by delivery through poly ( ethylene oxide )-block-poly ( ε-caprolactone ) copolymer-based micelles. J Appl Polym Sci. 2019;47769:1-9.
El-housiny S, Atef M, Eldeen S, et al. Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study. Drug Deliv. 2018;25(1):78-90.
Waghule T, Rapalli VK, Singhvi G, et al. Voriconazole loaded nanostructured lipid carriers based topical delivery system: QbD based designing, characterization, in-vitro and ex-vivo evaluation. J Drug Deliv Sci Technol. 2019;52:303-315.
Dave V, Sharma S, Bala R, Udita Y. Herbal liposome for the topical delivery of ketoconazole for the effective treatment of seborrheic dermatitis. Appl Nanosci. 2017;7(8):973-987.
Lemos CN, Pereira F, Dalmolin LF, Cubayachi C, Ramos DN, Lopez RFV. Chapter 6. Nanoparticles influence in skin penetration of drugs: in vitro and in vivo characterization. In: Grumezescu AM, ed. Nanostructures for the Engineering of Cells, Tissues and Organs. Oxford, UK: Elsevier Inc.; 2018:187-248.
Sala M, Diab R, Elaissari A, Fessi H. Lipid nanocarriers as skin drug delivery systems: properties, mechanisms of skin interactions and medical applications. Int J Pharm. 2018;535(1-2):1-17.
Mahmoud RA, Hussein AK, Nasef GA, Mansour HF. Oxiconazole nitrate solid lipid nanoparticles: formulation, in-vitro characterization and clinical assessment of an analogous loaded carbopol gel. Drug Dev Ind Pharm. 2020;46(5):706-716.
Carbone C, Fuochi V, Zielińska A, et al. Dual-drugs delivery in solid lipid nanoparticles for the treatment of Candida albicans mycosis. Colloids Surfaces B Biointerfaces. 2020;186:110705.
Ameeduzzafar QM, Alruwaili NK, SNA B, et al. BBD-based development of itraconazole loaded nanostructured lipid carrier for topical delivery: in vitro evaluation and antimicrobial assessment. J Pharm Innov. 2020;1-14.https://doi.org/10.1007/s12247-019-09420-5.
Gaba B, Fazil M, Khan S, Ali A, Baboota S, Ali J. Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bull Fac Pharm Cairo Univ. 2015;53(2):147-159.
Souto EB, Müller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul. 2005;22(5):501-510.
Sanap GS, Mohanta GP. Design and evaluation of miconazole nitrate loaded nanostructured lipid carriers (NLC ) for improving the antifungal therapy. J Appl Pharm Sci. 2013;3(01):46-54.
Fernandes AV, Pydi CR, Verma R, Jose J, Kumar L. Design, preparation and in vitro characterizations of fluconazole loaded nanostructured lipid carriers. Braz J Pharm Sci. 2020;56. https://doi.org/10.1590/s2175-97902019000318069.
Rocha ED, Ferreira MRS, dos Santos Neto E, et al. Enhanced in vitro antimicrobial activity of polymyxin B-coated nanostructured lipid carrier containing dexamethasone acetate. J Pharm Innov. 2020;1-11.https://doi.org/10.1007/s12247-020-09427-3.
de Oliveira JK, Ueda-Nakamura T, Corrêa AG, et al. Liposome-based nanocarrier loaded with a new quinoxaline derivative for the treatment of cutaneous leishmaniasis. Mater Sci Eng C. 2020;110:110720.
Pham H, Minh T, Thanh HN, Tuan QN, Le AT, Thanh TB. Development and evaluation of antifungal in vivo of liposomal amphotericin B. Int J Biol Chem. 2015;9(6):283-294.
El-badry M, Fetih G, Shakeel F. Comparative topical delivery of antifungal drug croconazole using liposome and micro-emulsion-based gel formulations. Drug Deliv. 2014;21:34-43.
Walker L, Sood P, Lenardon MD, et al. Crossm the viscoelastic properties of the fungal cell wall allow traffic of AmBisome as intact liposome vesicles. Am Soc Microbiol. 2018;9(1):1-15.
Sudhakar B, Varma JNR, Murthy KVR. Formulation, characterization and ex vivo studies of terbinafine HCl liposomes for cutaneous delivery formulation, characterization and ex vivo studies of terbinafine HCl liposomes for cutaneous delivery. Curr Drug Deliv. 2014;11:521-530.
Laurent A, Pantet O, Laurent L, et al. Potency and stability of liposomal amphotericin B formulated for topical management of Aspergillus spp. infections in burn patients. Burn Open. 2019. https://doi.org/10.1016/j.burnso.2019.09.001.
Singh M, Yellepeddi VK, Renukuntla J. Clotrimazole loaded Ufosomes for topical delivery: formulation development and in-vitro studies. Molecules. 2019;24:3139.
Dar MJ, Khalid S, McElroy CA, Satoskar AR, Khan GM. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes. Int J Pharm. 2020;573:118900.
Zhang P, Jing T, Zhang J. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral Candida albicans. Int J Nanomed. 2017;12:4269-4283.
Deng P, Teng F, Zhou F, Song Z, Meng N. Methoxy poly (ethylene glycol)-b-poly (δ-valerolactone) copolymeric micelles for improved skin delivery of ketoconazole. J Biomater Sci Polym Ed. 2016;28(1):63-78.
Abd-elsalam WH, Sally A, El-zahaby AMA. Formulation and in vivo assessment of terconazole-loaded polymeric mixed micelles enriched with Cremophor EL as dual functioning mediator for augmenting physical stability and skin delivery. Drug Deliv. 2018;25(1):484-492.
Guo Y, Karimi F, Fu Q, G. Qiao G, Zhang H. Reduced administration frequency for the treatment of fungal keratitis: a sustained natamycin release from a micellar solution. Expert Opin Drug Deliv 2020;17(3):407-421.
Benincasa M, Pacor S, Wu W, Prato ЌM, Bianco A, Gennaro R. Antifungal activity of amphotericin B conjugated to carbon nanotubes. ACS Nano. 2011;5(1):199-208.
Uttekar PS, Kulkarni AM, Sable PN. Surface modification of carbon nano tubes with nystatin for drug delivery applications. Int J Pharm Educ Res. 2016;50(3):385-390.
Mussin JE, Roldán MV, Rojas F, Sosa MÁ, Pellegri N, Giusiano G. Antifungal activity of silver nanoparticles in combination with ketoconazole against Malassezia furfur. AMB Express. 2019;9(1):131.
Home-ClinicalTrials.gov. Accessed May 20, 2020. https://clinicaltrials.gov/